Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement awards granted by its Compensation Committee to seven new employees on November 8, 2024. The awards include 56,100 non-qualified stock options at $42.00 per share and 28,050 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both awards require continued employment and were granted under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq: MIRM) ha annunciato premi di indennità concessi dal suo Comitato per la Compensazione a sette nuovi dipendenti l'8 novembre 2024. I premi includono 56.100 opzioni su azioni non qualificate a $42,00 per azione e 28.050 unità azionarie vincolate (RSU). Le opzioni su azioni matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il restante mese per mese nei 36 mesi successivi. Le RSU matureranno nel corso di tre anni, con il 33% che matura annualmente. Entrambi i premi richiedono un'occupazione continuativa e sono stati concessi nell'ambito del Piano di Indennità 2020 di Mirum, in conformità con la Regola 5635(c)(4) del Nasdaq.
Mirum Pharmaceuticals (Nasdaq: MIRM) anunció premios de incentivo otorgados por su Comité de Compensación a siete nuevos empleados el 8 de noviembre de 2024. Los premios incluyen 56,100 opciones de acciones no calificadas a $42.00 por acción y 28,050 unidades de acciones restringidas (RSUs). Las opciones de acciones se consolidarán durante cuatro años, con el 25% consolidando después de un año y el resto mensualmente durante 36 meses. Las RSUs se consolidarán durante tres años, con el 33% consolidando anualmente. Ambos premios requieren empleo continuo y fueron otorgados bajo el Plan de Inducción 2020 de Mirum, de acuerdo con la Regla 5635(c)(4) de Nasdaq.
미럼 제약회사 (Nasdaq: MIRM)는 2024년 11월 8일 보상 위원회가 7명의 새로운 직원에게 인센티브 보상을 수여했다고 발표했습니다. 보상에는 56,100개의 비자격 주식 옵션이 주당 $42.00과 28,050개의 제한 주식 단위 (RSUs)가 포함됩니다. 주식 옵션은 4년에 걸쳐 분할 지급되며, 1년 후 25%가 분할 지급되고 나머지는 36개월 동안 월별로 지급됩니다. RSUs는 3년에 걸쳐 분할 지급되며, 매년 33%가 분할 지급됩니다. 두 보상 모두 지속적인 근무가 필요하며, Nasdaq 상장 규정 5635(c)(4)에 따라 미럼의 2020 보상 계획에 따라 수여되었습니다.
Mirum Pharmaceuticals (Nasdaq: MIRM) a annoncé des récompenses d'incitation accordées par son Comité de Rémunération à sept nouveaux employés le 8 novembre 2024. Les récompenses comprennent 56 100 options d'achat d'actions non qualifiées au prix de 42,00 $ par action et 28 050 unités d'actions restreintes (RSUs). Les options sur actions acquièrent des droits sur quatre ans, avec 25 % qui acquièrent des droits après un an et le reste mensuellement pendant 36 mois. Les RSUs acquièrent des droits sur trois ans, avec 33 % qui acquièrent des droits chaque année. Les deux récompenses nécessitent une occupation continue et ont été accordées dans le cadre du Plan d'incitation 2020 de Mirum, conformément à la Règle d'inscription 5635(c)(4) du Nasdaq.
Mirum Pharmaceuticals (Nasdaq: MIRM) gab bekannt, dass am 8. November 2024 vom Vergütungsausschuss Anreizvergütungen an sieben neue Mitarbeiter vergeben wurden. Die Vergütungen umfassen 56.100 nicht qualifizierte Aktienoptionen zu einem Preis von 42,00 $ pro Aktie und 28.050 eingeschränkte Aktieneinheiten (RSUs). Die Aktienoptionen werden über vier Jahre vollständig vested, wobei 25% nach einem Jahr und der Rest monatlich über 36 Monate hinzugefügt wird. Die RSUs werden über drei Jahre vested, wobei jährlich 33% freigegeben werden. Beide Vergütungen erfordern eine fortlaufende Beschäftigung und wurden im Rahmen des Mirum Incentive Plans 2020 gemäß der Nasdaq Listungsregel 5635(c)(4) vergeben.
- Stock options granted at current market price ($42.00), aligning employee interests with shareholders
- Implementation of long-term vesting schedules promotes employee retention
- Potential shareholder dilution from issuance of new shares
Each stock option has an exercise price per share equal to
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108166937/en/
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
FAQ
How many stock options did MIRM grant in their November 2024 inducement awards?
What is the exercise price for MIRM's November 2024 inducement stock options?
What is the vesting schedule for MIRM's November 2024 RSU grants?